BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//ZContent.net//ZapCalLib 1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
SUMMARY:Thorium(IV) chelation for targeted alpha therapy
LOCATION:Chemistry A101
TZID:America/Denver
DTSTART:20191101T000000
UID:2026-04-04-18-39-41@natsci.colostate.edu
DTSTAMP:20260404T183941
Description:Literature Seminar\nTargeted alpha therapy represents an underd
 eveloped area of cancer treatment. Alpha particles have demonstrated a hig
 h degree of cytotoxicity\, which when harnessed\, can be effective at indu
 cing apoptosis in cancer cells. However\, due to the low natural abundance
  of alpha-emitting radioisotopes and their sparsely studied chemistry\, Ra
 dium-223 is the only FDA approved radioisotope for this purpose. Thorium-2
 27 is a promising alpha-emitting radioisotope that possesses some advantag
 es over Radium-223\, including a relatively high natural abundance and mor
 e extensive research of the coordination chemistry. To effectively utilize
  Thorium-227 for targeted alpha therapy\, it must be sequestered in a chel
 ator that binds both rapidly and irreversibly in physiological conditions.
  The Raymond group synthesized a novel chelator that combines design princ
 iples of several ligand structures to bind Th(IV). The kinetics and thermo
 dynamics of complexation under physiological conditions were studied to as
 sess the chelator’s potential use for targeted alpha therapy. 4:00 pm
END:VEVENT
END:VCALENDAR